MISHC 2025 Quarter 4 Meeting Summaries

Did you miss a meeting or do you need a refresher? Read our MISHC 2025 Quarter 4 meeting summaries here. You can also access the slides via the secure NextCloud link that was emailed to you.

Thank you for attending the 11/14/25 and 11/15/25 MSTCVS Quality Collaborative and MISHC Meeting and the MISHC Coordinator/Abstractor annual meeting! Listed below are a few highlights and key takeaways from these meetings.

Meeting Presentations:

  • Dr. Andrew Harris, MD, Michigan Medicine, presented Timing of Aortic Valve Intervention: A critical part of lifetime management of AS. The slides are available for you to review via NextCloud.
  • Joan Michaels, Director of ACC registries, presented the TVT national slide set. The slides are available for you to review via NextCloud.
  • Mollie Bodin, MISHC Co-Program Manager, presented the upcoming MISHC Interactive Reporting initiative design session.

MISHC Updates:
  • Update: Effective January 1, 2026, MISHC Coordinating Center will no longer email reports, data, or site correspondence to personal email addresses. Emails will only be sent to provider email addresses affiliated with hospital or provider sites.
  • Update: Effective with 2025 Q3 MISHC reporting, for a follow up to be considered complete, the following must be documented within the 23 – 75 day 30 day follow up window or the 305 – 425 1 year follow up window. 
    • Status – Alive or Deceased
    • Echo values of LVEF, AV Mean Gradient, Aortic Regurgitation and Paravalvular Regurgitation with a value
    • KCCQ values must be able to calculate at least one score, social, physical, symptom, or quality of life
    • NYHA Class documented as I, II, III, or IV

Thank you for attending the MISHC mitral workgroup breakout session on 11/15/25.

MISHC MTEER goals were reviewed with each member having their own data via the MISHC snapshot report. MISHC Collaborative performance for 2025 Q2 rolling 4 quarters is below. Refer to your site-specific snapshot for your own performance. The residual MR goal was discussed. Currently, TVT does not collect torrential MR as an option. TVT V4.0 set to release in 2026, torrential was suggested for addition to new version.

MISHC Mitral Goals are: Refractory to GDMT (Functional MTEER) >=75 - 79.2%, Shared Decision Making >=75% - 56.5%, Residual MR>= 2 at <=20% - 19.2%, Mean Gradient documented on 30-day follow-up at >=80% - 83.5%, Mean Gradient documented on 1-year follow-up at >=75% - 59.2%.

Current publication proposals and the publication process was reviewed. Guidelines and the publication proposal link are available on the publications and presentations page of mishc.org.

Remember to review the mitral and tricuspid data collection form when submitting proposals. You will find the form on the "Coordinator Resources" page at mishc.org.

Many publication topics were discussed and will be summarized for next Mitral Workgroup meeting.

MISHC Program Mentorship – an email will be sent to MISHC physicians asking if they would like to be a mentor or to be paired as a mentee.

Tricuspid Dashboard Draft and Reporting 2026 Q1 – Tricuspid data was reviewed for 2024 and 2025 Q1. Volumes are small at this time. Anticipate volumes will increase quickly. MISHC tricuspid reports targeted for 2026 Q1.

List of potential tricuspid variables to submit to TVT for addition to national data collection form include Torrential TR option, Report a 2 grade reduction in TR as successful procedure,

Jailed PPM leads, and additional RV function metrics pre-procedure to be outlined by Dr. Neal Duggal.

Next meeting December 9, 2025 at 5pm. Zoom invitation to follow.

 

Thank you for attending the MISHC TAVR workgroup breakout session on 11/15/25.

MISHC TAVR goals were reviewed with each member having their own data via the MISHC dashboard report. MISHC Collaborative performance for 2025 Q2 rolling 4 quarters is below. Refer to your site specific TAVR dashboard for your own performance.

MISHC TAVR Quality Goals: Echocardiogram Post-Procedure >=95% - 3,735, 3,757, 99.4%; 30-Day Follow Up Submission at >=95% - 3,627, 3,726, 97.3%; 1 Year Follow Up Submission at >=95% - 3249, 3479, 93.4%; Bleeding/Vascular Complications <=2% - 91, 3785, 2.4%; Transfusion at <=7% - 178, 3783, 4.7%; CV/eGFR >=3 (no concomitant proc) <=5% - 99, 3302, 3.0%; KCCQ at baseline and 30 D >=95% - 3336, 3570, 93.4%; NYHA class documented at 30 D >=92% - 3159, 3567, 88.6%

Current publication proposals and the publication process was reviewed. Guidelines and the publication proposal link are available on the "Publications and Presentations" page at mishc.org. Remember to review the TAVR data collection form when submitting proposals, you'll find it on the "Coordinator Resources" page at mishc.org.

Many publication topics were discussed and will be summarized at the next TAVR Workgroup meeting.

MISHC Mentorship – an email will be sent to MISHC physicians asking if they would like to be a mentor or to be paired as a mentee. The mentorship program and possible site visits will be discussed at the January TAVR workgroup meeting.

The next MISHC TAVR workgroup meeting will be January 9, 2025, at 6pm. Zoom invitation to follow.

 

MISHC MiTVT2 Webinar – October 21st from 10 – 11 am. Dr. Andrew Harris presented “Low Gradient Aortic Stenosis during the MISHC MiTVT2 Meeting on October 21st. You can view a recording of his talk on the MISHC YouTube Channel.